Registered Clinical Research on Neuroinflammatory Syndromes (NCT07145502)

BioCells Medical is officially listed as sponsor and clinical site of an observational clinical study registered on ClinicalTrials.gov (NCT07145502).This registration underlines our contribution to international research on cellular and exosome-based therapies for complex neuroinflammatory conditions.

About the Study

• Population: Children and adults aged 6–70 with autoinflammatory or post-infectious neuroinflammatory syndromes (including autoimmune encephalitis, post-viral encephalopathy, ME/CFS, and long COVID with CNS involvement).

• Innovation: Real-world monitoring of intravenous administration of allogeneic MSCs and MSC-derived exosomes, evaluating their potential to modulate inflammation and improve neurological outcomes.

• Design: Observational, non-randomized, 76 participants, with follow-up up to 24 months.

• Assessments: Neurological scales (NIHSS), cytokine profiles (IL-6, TNF-α), MRI findings, and quality of life (SF-36).
  

Why This Matters

Neuroinflammatory syndromes — including long COVID and post-infectious encephalopathies — represent a major challenge in modern medicine.Through this study, BioCells Medical provides systematic scientific data on cellular and exosome-based therapies, supporting global efforts to stabilize disease activity, reduce neuroinflammation, and improve quality of life for affected patients.

Global Recognition

Listing on ClinicalTrials.gov, the world’s largest clinical research registry maintained by the U.S. National Library of Medicine, affirms BioCells Medical’s role as an internationally recognized contributor to regenerative medicine research.